Undervaluing brain immune system is most likely hampering the success of cell therapy...
Updated: Dec 26, 2020
Together with the Stem cell and Regenerative's group at University of Barcelona, led by Prof. J.M. Canals and Professors Emanuele Cozzi (Università di Padova) and Anne E. Rosser (University of Cardiff), FRESCI published a deep through review on the status of cell therapies for two of the major neurodegenerative diseases, Parkinson's and Huntington's diseases.
Why is worth reading? To see what are the real world evidences and what has been done so far to cure PD and HD with cell therapy. It is a very complete review!
Why did we focus on the Immunological Response? So far, few researchers have deeply monitored the immune system role and activation when targeting the human brain with ATMPs. And we believe it is a crucial aspect for regenerative medicine success in neurodegenerative diseases.
How should you assess immunogenicity of your ATMP? Check out our future perspective section (p.21) to find tips on the standardization of your immunogenicity testing using a human-based approaches.